management of lower-risk mds without del5q and refractory to esas
Published 9 years ago • 107 plays • Length 25:10Download video MP4
Download video MP3
Similar videos
-
20:13
debate: hypomethylating agents are appropriate in lower-risk mds - only use with caution
-
24:04
my approach to mds management
-
2:37
esas for the management of lower-risk mds
-
14:55
novel treatment strategies in low-risk mds: q&a
-
23:17
erythropoiesis stimulating agents and other growth factors in low-risk mds: an update
-
7:51
lower risk mds
-
10:58
adnoc standard temporary defeat of hseces wms-5 #adnoc #safetyfirstlife #dubai #uae #hseengineers
-
17:13
hands-on with dvc | data versioning in mlops
-
7:54
patient/caregiver stories - living with mds
-
11:53
the optimal treatment of lower risk mds
-
1:34
perspectives on the management of low and high-risk mds
-
3:48
what are the treatment options for anemia in non-del(5q) low-risk mds patients?
-
1:48
the impact of esas in lower-risk mds
-
0:56
the promise of luspatercept for the treatment of lower-risk mds
-
20:03
my approach to mf management
-
1:26:55
emerging treatments for low-risk mds
-
22:41
new opportunities in experimental therapeutics in mds
-
2:12
improving the treatment of low-risk mds: luspatercept, treatment sequencing & disease classification
-
11:25
stop agents - m. mcclure, md
-
13:24
mutation-based risk stratification approaches in myelofibrosis: any real clinical utility?
-
3:39
configuring mde managed devices using microsoft intune configuration policies